<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9815831</journal-id>
<journal-id journal-id-type="pubmed-jr-id">22061</journal-id>
<journal-id journal-id-type="nlm-ta">Genet Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Genet. Med.</journal-id>
<journal-title-group>
<journal-title>Genetics in medicine : official journal of the American College of Medical Genetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">1098-3600</issn>
<issn pub-type="epub">1530-0366</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26716362</article-id>
<article-id pub-id-type="pmc">4929028</article-id>
<article-id pub-id-type="doi">10.1038/gim.2015.155</article-id>
<article-id pub-id-type="manuscript">NIHMS766156</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Mosaic mutations in early-onset genetic diseases</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Halvorsen</surname>
<given-names>Matt</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Petrovski</surname>
<given-names>Slavé</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shellhaas</surname>
<given-names>Renée</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tang</surname>
<given-names>Yingying</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Crandall</surname>
<given-names>Laura</given-names>
</name>
<degrees>MA</degrees>
<xref ref-type="aff" rid="A6">6</xref>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Goldstein</surname>
<given-names>David</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Devinsky</surname>
<given-names>Orrin</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Institute for Genomic Medicine, Columbia University, New York, New York, USA</aff>
<aff id="A2"><label>2</label>Department of Medicine, The University of Melbourne, Austin Health and Royal Melbourne Hospital, Melbourne, Victoria, Australia</aff>
<aff id="A3"><label>3</label>Division of Pediatric Neurology, C.S. Mott Children’s Hospital, University of Michigan, Ann Arbor, Michigan, USA</aff>
<aff id="A4"><label>4</label>Molecular Genetics Laboratory, New York City Office of the Chief Medical Examiner, New York, New York, USA</aff>
<aff id="A5"><label>5</label>Department of Pathology, NYU Langone Medical Center, New York, New York, USA</aff>
<aff id="A6"><label>6</label>SUDC Foundation, Herndon, Virginia, USA</aff>
<aff id="A7"><label>7</label>Comprehensive Epilepsy Center, Department of Neurology, NYU Langone Medical Center, New York, New York, USA</aff>
<author-notes>
<corresp id="cor1">Correspondence: Orrin Devinsky (<email>od4@nyu.edu</email>)</corresp>
<fn fn-type="equal" id="FN1">
<p id="P1">The first two authors contributed equally to this work.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>11</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="ppub">
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>7</month>
<year>2016</year>
</pub-date>
<volume>18</volume>
<issue>7</issue>
<fpage>746</fpage>
<lpage>749</lpage>
<!--elocation-id from pubmed: 10.1038/gim.2015.155-->
<abstract>
<sec id="S1">
<title>Purpose</title>
<p id="P2">An emerging approach in medical genetics is to identify de novo mutations in patients with severe early-onset genetic disease that are absent in population controls and in the patient’s parents. This approach, however, frequently misses post-zygotic “mosaic” mutations that are present in only a portion of the healthy parents’ cells and are transmitted to offspring.</p>
</sec>
<sec id="S2">
<title>Methods</title>
<p id="P3">We constructed a mosaic transmission screen for variants that have an ~50% alternative allele ratio in the proband but are significantly less than 50% in the transmitting parent. We applied it to two family-based genetic disease cohorts consisting of 9 cases of sudden unexplained death in childhood (SUDC) and 338 previously published cases of epileptic encephalopathy.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P4">The screen identified six parental-mosaic transmissions across the two cohorts. The resultant rate of ~0.02 identified transmissions per trio is far lower than that of de novo mutations. Among these transmissions were two likely disease-causing mutations: an <italic>SCN1A</italic> mutation transmitted to an SUDC proband and her sibling with Dravet syndrome, as well as an <italic>SLC6A1</italic> mutation in a proband with epileptic encephalopathy.</p>
</sec>
<sec id="S4">
<title>Conclusion</title>
<p id="P5">These results highlight explicit screening for mosaic mutations as an important complement to the established approach of screening for de novo mutations.</p>
</sec>
</abstract>
<kwd-group>
<kwd>epilepsy</kwd>
<kwd>mosaic</kwd>
<kwd>mutation</kwd>
<kwd>sudden unexplained death in childhood</kwd>
<kwd>whole-exome sequencing</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>